Clinical Investigation and Reports

Glycemic Control and Heart Failure Among Adult Patients With Diabetes

Carlos Iribarren, MD, MPH, PhD; Andrew J. Karter, PhD; Alan S. Go, MD; Assiamira Ferrara, MD, PhD; Jennifer Y. Liu, MPH; Stephen Sidney, MD, MPH; Joseph V. Selby, MD, MPH

Background—Glycemic control is associated with microvascular events, but its effect on the risk of heart failure is not well understood. We examined the association between hemoglobin (Hb) A\textsubscript{1c} and the risk of heart failure hospitalization and/or death in a population-based sample of adult patients with diabetes and assessed whether this association differed by patient sex, heart failure pathogenesis, and hypertension status.

Methods and Results—A cohort design was used with baseline between January 1, 1995, and June 30, 1996, and follow-up through December 31, 1997 (median 2.2 years). Participants were 25,958 men and 22,900 women with (predominantly type 2) diabetes, ≥19 years old, with no known history of heart failure. There were a total of 935 events (516 among men; 419 among women). After adjustment for age, sex, race/ethnicity, education level, cigarette smoking, alcohol consumption, hypertension, obesity, use of β-blockers and ACE inhibitors, type and duration of diabetes, and incidence of interim myocardial infarction, each 1% increase in Hb A\textsubscript{1c} was associated with an 8% increased risk of heart failure (95% CI 5% to 12%). An Hb A\textsubscript{1c} \textgreek{10}, relative to Hb A\textsubscript{1c} \textgreek{7}, was associated with 1.56-fold (95% CI 1.26 to 1.93) greater risk of heart failure. Although the association was stronger in men than in women, no differences existed by heart failure pathogenesis or hypertension status.

Conclusions—These results confirm previous evidence that poor glycemic control may be associated with an increased risk of heart failure among adult patients with diabetes. (Circulation. 2001;103:2668-2673.)

Key Words: heart failure n diabetes mellitus n glycemia n hemoglobin

The level of hemoglobin A\textsubscript{1c} (Hb A\textsubscript{1c}) is an index of metabolic control of diabetes.\textsuperscript{1} Elevated levels of Hb A\textsubscript{1c} indicate poor metabolic control and are associated with microvascular and neuropathic complications.\textsuperscript{2,3} Furthermore, lowering Hb A\textsubscript{1c} effectively delays the onset and slows the progression of these complications in patients with type 1\textsuperscript{4} and type 2\textsuperscript{5,6} diabetes.

Poor glycemic control may also predict macrovascular complications, including coronary heart disease among patients with type 2 diabetes.\textsuperscript{7,8} Furthermore, recent evidence from the UK Prospective Diabetes Study (UKPDS), a clinical trial sample, suggests that glycemic control is associated with increased risk of heart failure among patients with type 2 diabetes.\textsuperscript{9} Heart failure is a chronic condition closely linked to diabetes\textsuperscript{10} whose prevalence is increasing in the United States.\textsuperscript{11}

The aims of this study were 3-fold: first, to investigate the association between Hb A\textsubscript{1c} levels and heart failure incidence in a large, population-based sample of adult patients with diabetes; second, to examine whether the association is independent of established coronary and diabetes-related factors; and third, to ascertain whether the association of interest differed by patient sex, heart failure pathogenesis (ie, prior history of ischemic event[s]), and presence of hypertension.

Methods

Study Cohort

The Kaiser Permanente Medical Care Program of Northern California maintains a Diabetes Registry that includes all members of the health plan with diabetes mellitus. The Registry started in 1994 by identifying patients with diabetes mellitus from multiple automated databases and has a false-positive rate of 2.4\%.\textsuperscript{12} During 1994 through mid-1997, 94,024 Diabetes Registry members ≥19 years old received a health survey that included questions about behavioral, demographic, and clinical data.\textsuperscript{12,13} Obesity was defined as a body mass index ≥30 kg/m\textsuperscript{2}. Hypertension was ascertained by self-report. LDL cholesterol was estimated by the Friedewald equation,\textsuperscript{14} and HDL cholesterol was measured by an enzymatic colorimetric test (PEG-modified enzyme and sulfated cycloextrin). Hb A\textsubscript{1c} levels were measured from January 1, 1995, through October 31, 1995, by high-performance liquid chromatography (Diamat, Biorad Laborato-
ries) and by turbidimetric inhibition immunnoassay (Boehringer
Mannheim) between November 1, 1995, and June 30, 1996. The 2
methods were highly correlated (r=0.98).15

After exclusion of 3722 known false-positives, 83% [74 993/
(94 024−3722)] of noninstitutionalized, living, active Diabetes
Registry members responded to the survey. The study cohort consisted of a
subset of 69% of survey responders (n=51 680) who had ≥1
measurement of Hb A1c, between January 1, 1995, and June 30, 1996.
For patients with ≥1 measurement of Hb A1c in that period, only the
last measurement was used. Those who had a previous hospitalization
with primary or secondary diagnosis of heart failure during the
5 years before baseline were excluded from the analysis (n=2822).
The final sample for analysis comprised 48 858 adult patients with
diabetes (25 958 men and 22 900 women). Follow-up for heart
failure hospitalizations and for mortality from any cause was
complete through December 31, 1997 (median 2.2 years; range <1
year to 2.9 years). The study protocol was approved by the Kaiser
Foundation Institutional Review Board.

Study End Point

The primary study end point was a composite of hospitalization for
heart failure or death with heart failure as underlying cause. Incident
hospitalizations were captured by use of automated hospital primary
diagnosis of heart failure (International Classification of
Diseases, 9th revision [ICD-9] codes 428.x) or hypertensive heart
disease with heart failure (402.01, 402.11, 402.91) in all health plan
hospitals. Mortality from any cause, including death by heart failure
(same codes as hospitalizations), was ascertained by use of the
California Automated Mortality Linkage System.16

Previous ischemic event(s) during the 5 years before baseline were
ascertained through a search of hospitalizations as an inpatient
or outpatient diagnoses for ischemic heart disease (410.x to 414.x) and/or ischemic
stroke (433.x to 438.x) and/or revascularization procedures,
including coronary artery bypass graft surgery (36.1x), percutaneous
transluminal coronary angioplasty (36.0x), and carotid endarterec-
tomy (38.12).

To determine the validity of the primary discharge diagnosis of
heart failure in our hospitalization database, we randomly se-
lected 200 hospital charts of study participants and determined the
extent to which these cases met major and minor Framingham
criteria for heart failure.17 The most frequently encountered major
criteria for heart failure were rales (86.5%), and acute pulmonary edema (55%), and the most
frequent minor criteria were bilateral ankle edema (77.5%) and
dyspnea on ordinary exertion (96%). Overall, 92.5% of cases met
2 major and minor heart failure criteria; 89% met ≥1 major
and 2 minor criteria; and 97% met either of the 2 definitions
above. Thus, the positive predictive value of heart failure ascertainment
by hospital discharge codes was 97%, and the false-
positive rate was 3%. Because we did not review charts of
patients without heart failure, the sensitivity, specificity, and
negative predictive value of the ascertainment method by discharge
codes could not be determined.

Because atherosclerotic cardiovascular disease is a common
cause of heart failure, we also determined the extent to which hospitalization for heart failure was accompanied by either
unstable angina (411.1, 411.81, and 411.89) or acute myocardial
infarction (410.x).

Statistical Methods

Poisson regression was used to estimate sex-specific, age-
adjusted incidence rates of heart failure (per 1000 person-years)
according to the Hb A1c categories used before: <7%, 7% to
<8%, 8% to <9%, 9% to <10%, and ≥10%.9 Follow-up time
was calculated for each person from baseline to the time of heart
failure hospitalization (2%), death (5%), termination of health
plan membership (9%), or closing date (December 31, 1997)
(84%). Estimation of relative risks associated with categories of
Hb A1c (to assess threshold effects and nonlinear associations) and
for a 1 SD linear increase in Hb A1c and control for potential
confounders were done by sequential Cox proportional-hazards
models.18 Four models were considered: Model 1 was age- and
sex-adjusted. Model 2 was adjusted for age, sex, race/ethnicity
(black, Hispanic, Asian/Pacific Islander, and other/unknown,
versus white), level of education (less than high school, some
college, and unknown, versus college education or higher),
cigarette smoking (former, current, unknown, versus never),
alcohol consumption (never, former, occasional, light, heavy, and
unknown, versus moderate), self-reported hypertension, obesity,
and cardioprotective medication use at baseline (ACE inhibitor
and β-blockers). Adjustment for ACE inhibitors was performed
because of trials among patients with heart failure of left
ventricular dysfunction demonstrating reductions in the risk of
death, myocardial infarction, or hospital admission for heart
failure.19–22 Adjustment for β-blockers was done on the basis of recent
trials showing that use of β-blockers in addition to standard
therapy improved left ventricular function, reduced hospitaliza-
tions, and in the case of bisoprolol, long-acting metoprolol, and
carvedilol, improved survival in patients with chronic heart
failure.23,24 No adjustment was performed for LDL or HDL
cholesterol because of the large proportion of missing data on
these variables. However, we evaluated the effect of lipid
adjustment in a subset of cohort members with complete LDL and
HDL cholesterol values. Model 3 included additional covariates
diabetes type/treatment (type 1, type 2 on oral hypoglycemic
agents, type 2 on insulin, and unknown type/treatment, versus
type 2 on diet) and duration of diabetes (5 to 9 years, ≥10 years,
and unknown, versus ≤1 years). To ascertain the degree to which
the increased risk of heart failure associated with poor glycemic
control might be due to an interim cardiac event, model 4
included a dichotomous variable that represented incidence of
myocardial infarction during follow-up.

Formal tests for interaction in the Cox models were conducted to
assess whether the relationship between Hb A1c (as a continuous
variable) and heart failure risk differed by patient sex, history of
ischemic event(s), and presence of hypertension. Only the interaction
with patient sex was statistically significant (P=0.03), so results
stratifying by patient sex are also presented. All statistical analyses
were performed with SAS 6.11 (SAS Institute Inc).

Results

The mean age of the cohort was 58 years; 52% of men and
49% of women were white (Table 1). Men had a slightly
higher education level and a greater proportion of former
smokers than women. More women than men reported never consuming alcohol, and more men than
women reported either moderate or heavy alcohol consump-
tion. The distribution of diabetes type and treatment and the
duration of diabetes were similar between sexes.

The distribution of Hb A1c levels was comparable in men
and women: ≈22% were in poor glycemic control (ie, Hb A1c
≥10%). Women reported more hypertension and obesity and
had a higher prevalence of high LDL than men, whereas HDL
cholesterol was lower in men. Approximately 26% and 9%
used ACE inhibitors and β-blockers, respectively. No evi-
dence was found that those in poor glycemic control had
higher ACE inhibitor or β-blocker use (data not shown).

The number of nonfatal myocardial infarctions during follow-up,
as ascertained by primary hospital discharge diagnosis codes
410.x, was 1103 (2.3%), 682 in men (2.6%) and 421 in
women (1.8%).

After a median of 2.2 years of follow-up, 516 and 419
incident heart failure events were documented in men
and women, respectively. In men, there were 501 hospitalizations
with nonfatal heart failure, 9 hospitalizations with fatal heart
failure, and 6 deaths by heart failure without hospitalization.
In women, there were 411 hospitalizations with nonfatal heart failure, 3 hospitalizations with fatal heart failure, and 5 deaths by heart failure without hospitalization. Of the 924 hospitalizations with heart failure as the principal diagnosis, 825 (89%) did not have unstable angina or acute myocardial infarction as secondary diagnosis, and 99 (11%) had either unstable angina or acute myocardial infarction as secondary diagnosis.

Age-adjusted incidence rates of heart failure increased with increasing levels of Hb A1c in a monotonic fashion in both men ($P$ for linear trend $=0.0001$) and women ($P$ for linear trend $=0.009$) (Table 2). Only 2% (11/516) of incident heart failure events in men and 2% (10/419) in women occurred among patients with known type 1 diabetes.

After adjustment for age and sex, each 1% increase in Hb A1c was associated with a 12% increased risk of heart failure (95% CI 8% to 16%) (Table 3). Also in age- and sex-adjusted analysis, a concentration of Hb A1c $\geq 10$, relative to Hb A1c $<7$, was associated with a 1.83-fold (95% CI 1.48 to 2.25) greater risk of heart failure. Further adjustment for race/ethnicity, education level, cigarette smoking, alcohol consumption, hypertension, obesity, ACE inhibitors, $\beta$-blockers, diabetes type and duration, and interim myocardial infarction attenuated but did not explain the association.

Analysis stratifying by patient sex indicated that the association was stronger in men than in women ($P$ for interaction $=0.03$) (Table 3). In the fully adjusted analysis (model 4), the relative risk associated with a 1% increase in Hb A1c concentration was 1.12 (95% CI 1.07 to 1.18) in men and 1.04 (95% CI 0.98 to 1.09) in women; a concentration of Hb A1c $\geq 10$, relative to Hb A1c $<7$, was associated with a 1.8-fold increased heart failure risk in men compared with a 1.3-fold increased heart failure risk in women. No significant interactions were found between Hb A1c and having a history of ischemic event(s) ($P=0.52$) or between Hb A1c and hypertension status ($P=0.89$).

Adjustment for LDL and HDL cholesterol among those with complete lipid information (n=13 806; 252 events)

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Men (n=25 958)</th>
<th>Women (n=22 900)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Serum LDL, mmol/L</td>
<td>3.60±0.92</td>
<td>3.81±1.03</td>
</tr>
<tr>
<td>Serum HDL, mmol/L</td>
<td>0.88±0.23</td>
<td>1.09±0.31</td>
</tr>
</tbody>
</table>

Values are mean±SD or percent.
showed no attenuation of risk (data not shown). Furthermore, the predictive strength of Hb A\textsubscript{1c} was maintained when the analysis was restricted to the 825 hospitalizations in which heart failure was the principal diagnosis and there was no secondary diagnosis of unstable angina or acute myocardial infarction (RR per 1% increase in Hb A\textsubscript{1c} \(1.09\) [95% CI \(1.05\) to \(1.13\)] and RR of Hb A\textsubscript{1c} \(\geq 10\% \) versus \(7\% \) \(1.61\) [95% CI \(1.29\) to \(2.03\)])).

**Discussion**

This study suggests an independent, graded association between glycemic control and incidence of hospitalization and/or death due to heart failure among adult patients with diabetes and supports the recently published results in the UKPDS 35.\(^9\) Although the association was stronger in men than in women, we found a monotonic risk gradient in both sexes, with no evidence of a threshold level. The association persisted after adjustment for cardiovascular risk factors, use of \(\beta\)-blockers and ACE inhibitors at baseline, diabetes-related factors, and development of interim myocardial infarction during follow-up and was maintained in heart failure hospitalizations in which there was no secondary diagnosis of unstable angina or myocardial infarction.

Our findings are consistent with 2 interpretations. First, poor glycemic control may simply be a marker of worse **TABLE 2. Number of Events, Persons, Person-Years, and Age-Adjusted Rates per 1000 Person-Years of Heart Failure Hospitalization and/or Death by Hemoglobin A\textsubscript{1c} Concentration**

<table>
<thead>
<tr>
<th>Hemoglobin A\textsubscript{1c}, %</th>
<th>All (n=48 858)</th>
<th>Men (n=25 958)</th>
<th>Women (n=22 900)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Rate per 10(^3)</td>
<td>Rate per 10(^3)</td>
<td>Rate per 10(^3)</td>
</tr>
<tr>
<td></td>
<td>P-Y (95% CI)</td>
<td>P-Y (95% CI)</td>
<td>P-Y (95% CI)</td>
</tr>
<tr>
<td>&lt;7</td>
<td>145/10 631 21 963 4.5 (2.9–7.0)</td>
<td>81/5969 12 329 4.5 (2.5–8.2)</td>
<td>64/4662 9634 4.5 (2.4–8.6)</td>
</tr>
<tr>
<td>7 to &lt;8</td>
<td>197/10 692 23 417 5.8 (3.8–8.9)</td>
<td>107/5653 12 379 5.9 (3.2–10.6)</td>
<td>90/5039 11 038 5.6 (3.0–10.5)</td>
</tr>
<tr>
<td>8 to &lt;9</td>
<td>181/9238 20 808 6.3 (4.1–9.7)</td>
<td>93/4847 10 926 6.0 (3.3–10.9)</td>
<td>88/4391 9882 6.6 (3.5–12.2)</td>
</tr>
<tr>
<td>9 to &lt;10</td>
<td>172/7354 16 576 8.3 (5.5–12.6)</td>
<td>100/3817 8528 9.2 (5.2–16.4)</td>
<td>72/3537 8048 7.2 (3.9–13.4)</td>
</tr>
<tr>
<td>(\geq 10)</td>
<td>240/10 943 23 594 9.2 (6.2–13.8)</td>
<td>135/5672 12 059 10.3 (5.9–17.8)</td>
<td>105/5271 11 536 8.0 (4.4–14.5)</td>
</tr>
</tbody>
</table>

**TABLE 3. Age-, Sex-, and Multivariate-Adjusted Association Between Hemoglobin A\textsubscript{1c} and Heart Failure Hospitalization and/or Death**

<table>
<thead>
<tr>
<th>Hemoglobin A\textsubscript{1c}, %</th>
<th>Model 1</th>
<th>Model 2</th>
<th>Model 3</th>
<th>Model 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>All (n=48 858; 935 events)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;7</td>
<td>1 1.20 (0.97–1.48)</td>
<td>1.21 (0.98–1.50)</td>
<td>1.15 (0.92–1.42)</td>
<td>1.15 (0.93–1.43)</td>
</tr>
<tr>
<td>7 to &lt;8</td>
<td>1.25 (1.01–1.56)</td>
<td>1.26 (1.01–1.57)</td>
<td>1.12 (0.89–1.39)</td>
<td>1.10 (0.88–1.38)</td>
</tr>
<tr>
<td>8 to &lt;9</td>
<td>1.64 (1.31–2.04)</td>
<td>1.62 (1.30–2.03)</td>
<td>1.42 (1.13–1.78)</td>
<td>1.39 (1.11–1.74)</td>
</tr>
<tr>
<td>9 to &lt;10</td>
<td>1.83 (1.48–2.25)</td>
<td>1.80 (1.45–2.22)</td>
<td>1.57 (1.27–1.95)</td>
<td>1.56 (1.26–1.93)</td>
</tr>
<tr>
<td>(\geq 10)</td>
<td>1.12 (1.08–1.16)</td>
<td>1.11 (1.07–1.15)</td>
<td>1.09 (1.05–1.13)</td>
<td>1.08 (1.05–1.12)</td>
</tr>
</tbody>
</table>

**Men (n=25 958; 516 events)**

| <7                              | 1 1.22 (0.92–1.63) | 1.24 (0.93–1.65) | 1.17 (0.87–1.56) | 1.18 (0.88–1.58) |
| 7 to <8                         | 1.23 (0.91–1.65) | 1.23 (0.91–1.65) | 1.08 (0.80–1.47) | 1.07 (0.79–1.46) |
| 8 to <9                         | 1.85 (1.38–2.48) | 1.85 (1.38–2.49) | 1.62 (1.20–2.19) | 1.61 (1.19–2.18) |
| \(\geq 10\)                     | 2.11 (1.60–2.79) | 2.06 (1.56–2.73) | 1.79 (1.35–2.39) | 1.80 (1.35–2.40) |

**Women (n=22 900; 419 events)**

| <7                              | 1 1.15 (0.84–1.59) | 1.18 (0.86–1.63) | 1.12 (0.81–1.54) | 1.11 (0.80–1.53) |
| 7 to <8                         | 1.27 (0.92–1.75) | 1.30 (0.94–1.80) | 1.16 (0.83–1.61) | 1.13 (0.81–1.57) |
| 8 to <9                         | 1.39 (0.99–1.95) | 1.37 (0.98–1.93) | 1.20 (0.85–1.69) | 1.15 (0.81–1.63) |
| \(\geq 10\)                     | 1.53 (1.11–2.09) | 1.54 (1.12–2.11) | 1.36 (0.98–1.87) | 1.32 (0.95–1.82) |

Values are hazard ratio (95% CI). See methods for covariates included in each model.
Hyperglycemia may be linked to atherogenesis through modification of LDL lipoproteins by advanced glycosylation end products,25 endothelial dysfunction,26 increased plasminogen activator inhibitor 1, von Willebrand factor and platelet aggregation,27 and dyslipidemia with increased production of VLDL, low plasma HDL, and high plasma levels of small, dense LDL.28

Clinical-pathological work has described a specific form of cardiomyopathy in patients with diabetes, thought to be caused by microangiopathy29 and by cellular changes in calcium transport and fatty acid metabolism.30 Also, several studies have demonstrated abnormalities of left ventricular mechanical function (primarily diastolic) in patients with diabetes without known coronary artery disease.31

Our study has several limitations. First, the follow-up time was relatively short, but this was compensated by a large sample size. Because the progression to clinical heart failure may be longer than 2 years, it is likely that some diabetic patients in the study had preclinical heart failure at baseline. The likelihood of bias due to disease at baseline was minimized, however, by the exclusion of patients with documented heart failure up to 5 years before baseline. Second, because of the small number of events among them, we were unable to make inferences about the association between glycemic control and heart failure among patients with type 1 diabetes. Third, because the ascertainment of outcome was based on hospitalization and/or death, less severe or subclinical heart failure (ie, not requiring hospitalization or showing asymptomatic left ventricular dysfunction) were not considered. Fourth, the analysis was based on a single measurement of Hb A1c, although Hb A1c is indicative of the time-averaged blood glucose concentration over the past 3 months. First, we were unable to characterize the severity of heart failure in terms of left ventricular function (ie, ejection fraction) or functional status (ie, New York Heart Association class), because this information was not available in our clinical databases. Finally, the proportion of participants with missing data for lipid values was quite high; nonetheless, adjustment for LDL and HDL cholesterol in subset analysis had only a marginal effect.

Our findings may have important clinical and public health implications. First, although it is yet to be determined by clinical trials, our results suggest that tight glycemic control may potentially reduce the incidence of heart failure. Second, because no Hb A1c threshold could be identified, our data suggest that it might be desirable to achieve levels of glycemia as close to the normoglycemic range as possible (ie, Hb A1c <7%). This potential benefit of tight metabolic control of diabetes should be weighed against existing barriers to glycemic control, including fear of hypoglycemia and, in women, weight gain.32

Acknowledgments
This study was supported by Kaiser Foundation Research Institute and the American Diabetes Association. We are indebted to Catalina Magallon for performing the medical chart review.

References


Glycemic Control and Heart Failure Among Adult Patients With Diabetes
Carlos Iribarren, Andrew J. Karter, Alan S. Go, Assiamira Ferrara, Jennifer Y. Liu, Stephen Sidney and Joseph V. Selby

Circulation. 2001;103:2668-2673
doi: 10.1161/01.CIR.103.22.2668
Circulation is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2001 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7322. Online ISSN: 1524-4539

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circ.ahajournals.org/content/103/22/2668

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation is online at:
http://circ.ahajournals.org//subscriptions/